BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28885787)

  • 1. An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation.
    Acharya AP; Theisen KM; Correa A; Meyyappan T; Apfel A; Sun T; Tarin TV; Little SR
    Adv Healthc Mater; 2017 Nov; 6(22):. PubMed ID: 28885787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria.
    Piao XM; Jeong P; Kim YH; Byun YJ; Xu Y; Kang HW; Ha YS; Kim WT; Lee JY; Woo SH; Kwon TG; Kim IY; Moon SK; Choi YH; Cha EJ; Yun SJ; Kim WJ
    Int J Cancer; 2019 Jan; 144(2):380-388. PubMed ID: 30183088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria.
    Karnes RJ; Fernandez CA; Shuber AP
    Mayo Clin Proc; 2012 Sep; 87(9):835-42. PubMed ID: 22883743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of patients with microscopic hematuria who are at greater risk for the presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey.
    Turkeri L; Mangir N; Gunlusoy B; Yildirim A; Baltaci S; Kaplan M; Bozlu M; Mungan A
    Asian Pac J Cancer Prev; 2014; 15(15):6283-6. PubMed ID: 25124612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ; Fisher HA; Kogan BA
    J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
    Cariou G; Maaraoui N; Cortesse A
    Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.
    van Kessel KE; Van Neste L; Lurkin I; Zwarthoff EC; Van Criekinge W
    J Urol; 2016 Mar; 195(3):601-7. PubMed ID: 26327355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
    Shirodkar SP; Lokeshwar VB
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1111-23. PubMed ID: 18588456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
    Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
    Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
    Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
    Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
    Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
    Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
    Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
    Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
    Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
    Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.